Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.58 |
| ▸ | EP300 | Q09472 | 2/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | TSPO | P30536 | 1/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28720346 | 1.00 | BRD4 (0.58) | BRD4EP300CYP17A1BRD2ADORA2B | |
| SCHEMBL29548942 | 0.90 | BRD4 (0.65) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL28720367 | 0.90 | BRD4 (0.65) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL29548701 | 0.87 | BRD4 (0.57) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL28718892 | 0.87 | BRD4 (0.57) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL29548631 | 0.86 | BRD4 (0.56) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL29548880 | 0.85 | BRD4 (0.59) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL28720340 | 0.85 | BRD4 (0.59) | BRD4EP300BRD2ADORA2BTSPO | |
| SCHEMBL29548625 | 0.85 | BRD4 (0.50) | BRD4EP300BRD2BRD3BRDT | |
| SCHEMBL28718931 | 0.85 | BRD4 (0.50) | BRD4EP300BRD2BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110041253-B | Pyridine N-oxide derivative and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-03-29 | — | — | CN | disclosed |